Stephan A. Grupp

Stephan Grupp is a pioneer in pediatric CAR-T cell therapy who led clinical trials resulting in the first FDA approval of CAR-T cell therapy (Kymriah/tisagenlecleucel) for pediatric ALL. His work at CHOP transformed treatment of relapsed childhood leukemia and established frameworks for managing CAR-T toxicities.

Stephan Grupp是儿童CAR-T细胞治疗的先驱，领导的临床试验导致了第一个FDA批准的CAR-T细胞治疗（Kymriah/tisagenlecleucel）用于儿童ALL。他在费城儿童医院的工作改变了复发性儿童白血病的治疗，并建立了管理CAR-T毒性的框架。